Prosecution Insights
Last updated: April 19, 2026
Application No. 17/988,192

INTRODUCER WITH SALINE ANTECHAMBER

Non-Final OA §102§103§112
Filed
Nov 16, 2022
Examiner
STIMPERT, PHILIP EARL
Art Unit
3783
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
BOSTON SCIENTIFIC CORPORATION
OA Round
3 (Non-Final)
63%
Grant Probability
Moderate
3-4
OA Rounds
3y 9m
To Grant
99%
With Interview

Examiner Intelligence

Grants 63% of resolved cases
63%
Career Allow Rate
537 granted / 857 resolved
-7.3% vs TC avg
Strong +49% interview lift
Without
With
+49.3%
Interview Lift
resolved cases with interview
Typical timeline
3y 9m
Avg Prosecution
85 currently pending
Career history
942
Total Applications
across all art units

Statute-Specific Performance

§101
0.4%
-39.6% vs TC avg
§103
50.1%
+10.1% vs TC avg
§102
20.5%
-19.5% vs TC avg
§112
26.7%
-13.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 857 resolved cases

Office Action

§102 §103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 12 February 2025 has been entered. The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 1-20 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. Regarding claim 1, the limitation of “an outer surface of the medical device is exposed within the antechamber” is not present in the application as originally filed. The examiner notes that the limitation is negative in nature and as such generally explicit support is required to demonstrate possession. See MPEP 2173.05(i). Regarding claim 11, the limitation of “an outer surface of the medical device is uncovered within the interior of antechamber[sic]” is not present in the application as originally filed. The examiner notes that the limitation is negative in nature and as such generally explicit support is required to demonstrate possession. Regarding claim 17, the limitation of “the antechamber is free of a tubular body extending therein between the first hemostasis valve and the second hemostasis valve” is not present in the application as originally filed. The examiner notes that the limitation is negative in nature and as such generally explicit support is required to demonstrate possession. Additionally, it is unclear how the medical device is not a “tubular body” extending as claimed. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 1, 8-10, 17 and 20 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by US Patent 10,500,349 to Shivkumar et al. (Shivkumar hereinafter). Regarding claim 1, Shivkumar teaches an introducer assembly (see e.g. Fig. 11) comprising an introducer body (504) adapted to accommodate a volume of fluid therein, an antechamber (1104) therein, a first hemostasis valve (1130) and a second hemostasis valve (506) respectively disposed proximal of and distal of the antechamber and adapted to allow a medical device (904) to pass therethrough (col. 12, ln. 33-60), the first communicating the introducer body with the antechamber. Shivkumar further teaches that the antechamber is filled with liquid such as saline (see e.g. col. 11, ln. 14-27) and that any air trapped therein can be drawn out through the associated check valve 1112 (col. 11, ln. 39-42). Further, Shivkumar teaches that the introducer body is also filled with liquid such as saline (col. 11, ln. 1-13) and that any air therein may be drawn out through the associated check valve (512). Taken together with the teaching that the valves of Shivkumar define the introduction path and bound the wet portion of the apparatus, Shivkumar teaches a wet path passing sequentially through the first hemostasis valve (1130), the antechamber, and the second hemostasis valve (506), and that it is substantially filled with saline providing a continuous liquid interface for the medical device. As best understood, an exterior, or outer, surface of the medical device (904) is exposed (e.g. to the saline) within the antechamber. Regarding claim 8, Shivkumar teaches luer fittings (512, 514, 1112) disposed at different locations relative to the periphery of the antechamber, and thus disposed about the periphery. Regarding claim 9, Shivkumar teaches that the luer fittings are adapted to be used to introduce saline into the antechamber, for instance via the use of a catheter similar to the catheter (904, Fig. 11). Regarding claim 10, Shivkumar teaches that one of the luer fittings (1112) is adapted to bleed air out of the antechamber (col. 14, ln. 1-2). Regarding claim 17, Shivkumar teaches an introducer assembly (see e.g. Fig. 11) comprising an introducer body (504) adapted to accommodate a volume of fluid therein, an antechamber (1104) therein, a first hemostasis valve (1130) and a second hemostasis valve (506) respectively disposed proximal of and distal of the antechamber and adapted to allow a medical device (904) to pass therethrough (col. 12, ln. 33-60), the first communicating the introducer body with the antechamber. Shivkumar further teaches that the antechamber (1104) is adapted to hold a volume of saline sufficient to submerge a path along which the medical device (904) may travel and to permit air to be purged. The examiner notes that adaptation to hold liquid requires only a solid surface or a surface with all but one opening being sealable. Shivkumar further teaches that the antechamber is filled with liquid such as saline (see e.g. col. 11, ln. 14-27) and that any air trapped therein can be drawn out through the associated check valve 1112 (col. 11, ln. 39-42). Further, Shivkumar teaches that the introducer body is also filled with liquid such as saline (col. 11, ln. 1-13) and that any air therein may be drawn out through the associated check valve (512). Taken together with the teaching that the valves of Shivkumar define the introduction path and bound the wet portion of the apparatus, Shivkumar teaches a wet path passing sequentially through the first hemostasis valve (1130), the antechamber, and the second hemostasis valve (506), and that it is substantially filled with saline providing a continuous liquid interface for the medical device. Furthermore, as the core tube (1102) is not strictly tubular, the examiner holds that the antechamber of Shivkumar is substantially free of a tubular body extending between the first hemostasis valve and the second hemostasis valve. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claim(s) 2-7, 11-16 and 18-20 is/are rejected under 35 U.S.C. 103 as being unpatentable over Shivkumar. Regarding claims 2 and 18, Shivkumar teaches the limitations of claims 1 and 17 from which these claims depend, but does not explicitly teach annular chambers having the claimed major and minor axes. However, the examiner notes that applicant has not established any particular criticality to these limitations. The examiner further notes that where the difference between the prior art and the claimed invention is a matter of shape, there is no patentable distinction absent evidence that the shape is significant (MPEP 2144.04 IV. B). Accordingly, since Shivkumar teaches an axis of introduction (e.g. right to left in Fig. 11), the only difference between the prior art and the claimed invention is a shape for which there is not persuasive evidence of criticality. The examiner notes that applicant has specifically noted that changes in shape are possible (paragraph 51 of applicant’s specification). The examiner therefore concludes that these claims are obvious over Shivkumar as, at most, a change in shape that does not rise to the level of patentability. Regarding claims 3, 6-7 and 19, Shivkumar teaches that the axis of introduction extends as claimed (see Fig. 11, axis of introduction extending through the centers of 504 and 1104 from right to left). Regarding claims 4 and 20, Shivkumar teaches that the major axis is vertical to allow air to rise to the relevant valve (see Fig. 10, col. 10, ln. 47-55) and the level of saline is sufficient to enforce the rising action. Regarding claim 11, Shivkumar teaches an introducer assembly (see e.g. Fig. 11) comprising an introducer body (504) adapted to accommodate a volume of fluid therein, an antechamber (1104) therein, a first hemostasis valve (1130) and a second hemostasis valve (506) respectively disposed proximal of and distal of the antechamber and adapted to allow a medical device (904) to pass therethrough (col. 12, ln. 33-60), the first communicating the introducer body with the antechamber. Shivkumar further teaches that the antechamber (1104) is adapted to hold a volume of saline sufficient to submerge a path along which the medical device (904) may travel and to permit air to be purged. The examiner notes that adaptation to hold liquid requires only a solid surface or a surface with all but one opening being sealable. Shivkumar further teaches that the antechamber is filled with liquid such as saline (see e.g. col. 11, ln. 14-27) and that any air trapped therein can be drawn out through the associated check valve 1112 (col. 11, ln. 39-42). Further, Shivkumar teaches that the introducer body is also filled with liquid such as saline (col. 11, ln. 1-13) and that any air therein may be drawn out through the associated check valve (512). Taken together with the teaching that the valves of Shivkumar define the introduction path and bound the wet portion of the apparatus, Shivkumar teaches a wet path passing sequentially through the first hemostasis valve (1130), the antechamber, and the second hemostasis valve (506), and that it is substantially filled with saline providing a continuous liquid interface for the medical device. As best understood, an exterior, or outer, surface of the medical device (904) is uncovered (e.g. with respect to the saline) within the antechamber. Furthermore, Shivkumar teaches a wet path passing sequentially through the first hemostasis valve (1130), the antechamber, and the second hemostasis valve (506), and that it is substantially filled with saline providing a continuous liquid interface for the medical device. Regarding claims 5 and 12, as noted above, Shivkumar teaches that the antechamber is filled with liquid such as saline (see e.g. col. 11, ln. 14-27) and that any air trapped therein can be drawn out through the associated check valve 1112 (col. 11, ln. 39-42) such that the wet path will be submerged. Regarding claim 13, Shivkumar teaches purging of air (via 1112). Regarding claim 14, Shivkumar teaches luer fittings (512, 514, 1112) disposed at different locations relative to the periphery of the antechamber, and thus disposed about the periphery. Regarding claim 15, Shivkumar teaches that the luer fittings are adapted to be used to introduce saline into the antechamber, for instance via the use of a catheter similar to the catheter (904, Fig. 11). Regarding claim 16, Shivkumar teaches that one of the luer fittings (1112) is adapted to bleed air out of the antechamber (col. 14, ln. 1-2). Claim(s) 2-4, 6-7, 11-16, and 18-20 is/are rejected under 35 U.S.C. 103 as being unpatentable over Shivkumar in view of U.S. Patent 9,078,981 to Subramaniam et al. (Subramaniam). Regarding claims 2-3, 11, and 18-19, Shivkumar teaches the limitations of claim 1 from which claim 2 depends, but does not teach that the antechamber has an annular body with a major and minor dimension, the major dimension being perpendicular with an axis of insertion (i.e. path of 904 in Shivkumar). Subramaniam teaches another medical device generally, and particularly teaches that an antechamber (105) may have an annular body (130) with a major dimension perpendicular to the insertion axis (MD). Subramaniam teaches that this allows for inhibition of gas infiltration (col. 2, ln. 6-32). One of ordinary skill in the art would have found it obvious before the effective filing date of the application to provide an annular body as taught by Subramaniam either instead of or in addition to the antechamber of Shivkumar in order to assist in preventing gas infiltration. Regarding claims 4, 12, Shivkumar teaches that the antechamber (1104) is adapted to hold a volume of saline sufficient to submerge a path along which the medical device (904) may travel and to permit air to be purged. The examiner notes that adaptation to hold liquid requires only a solid surface or a surface with all but one opening being sealable. Regarding claims 6-7, Shivkumar teaches that the axis of introduction extends as claimed (see Fig. 11, axis of introduction extending through the centers of 504 and 1104 from right to left). Regarding claim 13, Shivkumar teaches that one of the luer fittings (1112) is adapted to bleed air out of the antechamber (col. 14, ln. 1-2) upon entry of sufficient saline. Regarding claim 14, Shivkumar teaches luer fittings (512, 514, 1112) disposed at different locations relative to the periphery of the antechamber, and thus disposed about the periphery. Regarding claim 15, Shivkumar teaches that the luer fittings are adapted to be used to introduce saline into the antechamber, for instance via the use of a catheter similar to the catheter (904) of Fig. 11. Regarding claim 16, Shivkumar teaches that one of the luer fittings (1112) is adapted to bleed air out of the antechamber (col. 14, ln. 1-2). Regarding claim 20, Shivkumar teaches that the major axis is vertical to allow air to rise to the relevant valve (see Fig. 10, col. 10, ln. 47-55) and the level of saline is sufficient to enforce the rising action. Response to Arguments Applicant's arguments filed 12 February 2026 have been fully considered but they are not persuasive. With respect to the new limitations, the examiner notes that these are, first, held to contain new matter. Second, Shivkumar teaches these limitations as discussed above, at least to the standard of a broadest reasonable interpretation thereof. With respect to claim 1, an outer surface of the medical device is exposed, at least to the saline in the antechamber. With respect to claim 11, such an outer surface is uncovered within the antechamber, and the presence of the core tube does not meaningfully affect this uncovered state. With respect to the tubular member of claim 17, this appears to require a tubular member extending from one valve to the second. However, since 1102 bulges in the middle and is perforated, this does not qualify as such an excluded body. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to PHILIP E STIMPERT whose telephone number is (571)270-1890. The examiner can normally be reached Monday-Friday, 8a-4p. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Chelsea Stinson can be reached at 571-270-1744. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /PHILIP E STIMPERT/Primary Examiner, Art Unit 3783 4 April 2026
Read full office action

Prosecution Timeline

Nov 16, 2022
Application Filed
May 30, 2025
Non-Final Rejection — §102, §103, §112
Sep 03, 2025
Response Filed
Dec 10, 2025
Final Rejection — §102, §103, §112
Feb 12, 2026
Response after Non-Final Action
Mar 11, 2026
Request for Continued Examination
Mar 31, 2026
Response after Non-Final Action
Apr 04, 2026
Non-Final Rejection — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12577961
LOW-FLOW FLUID DELIVERY SYSTEM AND LOW-FLOW DEVICE THEREFOR
2y 5m to grant Granted Mar 17, 2026
Patent 12573932
LINEAR MOTOR AND LINEAR COMPRESSOR
2y 5m to grant Granted Mar 10, 2026
Patent 12560168
VARIABLE DISPLACEMENT PUMP
2y 5m to grant Granted Feb 24, 2026
Patent 12560173
MOTOR AND APPARATUS USING THE SAME
2y 5m to grant Granted Feb 24, 2026
Patent 12529366
MEMBRANE PUMP
2y 5m to grant Granted Jan 20, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
63%
Grant Probability
99%
With Interview (+49.3%)
3y 9m
Median Time to Grant
High
PTA Risk
Based on 857 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month